Brief: Ocumension Therapeutics Says Total Revenue Was Rmb13.1 Mln For Year
19/03/2021 15:14
March 19 (Reuters) - Ocumension Therapeutics 1477.HK :
* TOTAL REVENUE WAS RMB13.1 MILLION FOR YEAR
* FY LOSS AND TOTAL COMPREHENSIVE EXPENSE ATTRIBUTABLE
RMB2.26
BILLION VERSUS LOSS RMB1.31 BILLION
Source text for Eikon: urn:newsml:reuters.com:*:nHKS1b787n
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application